Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.

Teo JT, Edwards MJ, Bhatia K.

Mov Disord. 2012 Sep 1;27(10):1205-15. doi: 10.1002/mds.25107. Epub 2012 Aug 1. Review.

PMID:
22865512
2.

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, Picconi B, Gardoni F, Usiello A.

Exp Neurol. 2011 Dec;232(2):240-50. doi: 10.1016/j.expneurol.2011.09.013. Epub 2011 Sep 17.

PMID:
21946266
3.

Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

Cho CH, Lee HJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:207-13. doi: 10.1016/j.pnpbp.2012.10.018. Epub 2012 Oct 31. Review.

PMID:
23123399
4.

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT.

Am J Psychiatry. 1998 Sep;155(9):1207-13.

PMID:
9734544
5.

[Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].

Seigneurie AS, Sauvanaud F, Limosin F.

Encephale. 2016 Jun;42(3):248-54. doi: 10.1016/j.encep.2015.12.021. Epub 2016 Feb 26. Review. French.

PMID:
26922134
6.

Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Mahmoudi S, Lévesque D, Blanchet PJ.

Mov Disord. 2014 Aug;29(9):1125-33. doi: 10.1002/mds.25909. Epub 2014 May 16.

7.

Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.

Bishnoi M, Chopra K, Kulkarni SK.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):451-61. Epub 2007 Sep 29.

PMID:
17988775
8.

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

Glazer WM.

J Clin Psychiatry. 2000;61 Suppl 3:16-21. Review.

9.

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.

Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R.

Can J Psychiatry. 2005 Aug;50(9):541-7. Review.

PMID:
16262110
10.

Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.

Picconi B, Ghiglieri V, Bagetta V, Barone I, Sgobio C, Calabresi P.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S145-9. doi: 10.1016/j.parkreldis.2008.04.019. Epub 2008 Jun 25. Review.

PMID:
18583173
11.

Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine.

Mao LM, Wang W, Chu XP, Zhang GC, Liu XY, Yang YJ, Haines M, Papasian CJ, Fibuch EE, Buch S, Chen JG, Wang JQ.

Nat Neurosci. 2009 May;12(5):602-10. doi: 10.1038/nn.2300. Epub 2009 Apr 6.

12.

Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.

Mahmoudi S, Blanchet PJ, Lévesque D.

Eur J Neurosci. 2013 Jul;38(1):2192-8. doi: 10.1111/ejn.12198. Epub 2013 Mar 31.

13.

Pathophysiological mechanisms underlying tardive dyskinesia.

Gerlach J.

Psychopharmacology Suppl. 1985;2:98-103.

PMID:
2860666
14.

Tardive dyskinesia: clinical, biological, and pharmacological perspectives.

Berger PA, Rexroth K.

Schizophr Bull. 1980;6(1):102-16.

PMID:
6102788
15.

Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting.

Coplan J, Gugger JJ, Tasleem H.

J Affect Disord. 2013 Sep 25;150(3):868-71. doi: 10.1016/j.jad.2013.04.053. Epub 2013 May 30.

PMID:
23726783
16.

Tardive dyskinesia: a role for the endogenous opioid system.

Sandyk R.

Med Hypotheses. 1986 Jan;19(1):71-4.

PMID:
2871480
17.

The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.

Lindenbach D, Conti MM, Ostock CY, George JA, Goldenberg AA, Melikhov-Sosin M, Nuss EE, Bishop C.

J Neurosci. 2016 Sep 21;36(38):9873-87. doi: 10.1523/JNEUROSCI.1318-16.2016.

18.

Neuroleptic drugs and their action on different neuronal pathways.

Ungerstedt U, Herrera-Marschitz M, Forster C.

J Clin Psychiatry. 1985 Apr;46(4 Pt 2):34-7.

PMID:
2858478
19.

Synaptic dysfunction in Parkinson's disease.

Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B.

Biochem Soc Trans. 2010 Apr;38(2):493-7. doi: 10.1042/BST0380493. Review.

PMID:
20298209
20.

Altered cortico-striatal synaptic plasticity and related behavioural impairments in reeler mice.

Marrone MC, Marinelli S, Biamonte F, Keller F, Sgobio CA, Ammassari-Teule M, Bernardi G, Mercuri NB.

Eur J Neurosci. 2006 Oct;24(7):2061-70.

PMID:
17067303

Supplemental Content

Support Center